Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase

Studies on the mode of action of a series of bisphosphonates derived from fatty acids, which had previously proved to be potent inhibitors against Trypanosoma cruzi proliferation in in vitro assays, have been performed. Some of these drugs proved to be potent inhibitors against the intracellular for...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Szajnman, S.H
Otros Autores: Montalvetti, A., Wang, Y., Docampo, R., Rodriguez, J.B
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: Elsevier Ltd 2003
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 08581caa a22011897a 4500
001 PAPER-4815
003 AR-BaUEN
005 20230518203424.0
008 190411s2003 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0041330424 
024 7 |2 cas  |a geranyltransferase, 37277-79-5, 50812-36-7 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a BMCLE 
100 1 |a Szajnman, S.H. 
245 1 0 |a Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase 
260 |b Elsevier Ltd  |c 2003 
270 1 0 |m Rodriguez, J.B.; Depto. de Quím. Orgán., Fac. de Ciencias Exactas y Naturales, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina; email: jbr@qo.fcen.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Moncayo, A., (1995) Eleventh Programme Report of the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR), , Geneva: World Health Organization. p 67 
504 |a Brener, Z., (1973) Annu Rev. Microbiol., 27, p. 347 
504 |a De Souza, W., (1984) Int. Rev. Cytol., 86, p. 197 
504 |a Docampo, R., Schmuñis, G.A., (1997) Parasitol. Today, 13, p. 129 
504 |a De Castro, S.L., (1993) Acta Trop., 53, p. 83 
504 |a Brener, Z., (1979) Pharmacol. Ther., 7, p. 71 
504 |a Rodriguez, J.B., Gros, E.G., (1995) Curr. Med. Chem., 2, p. 723 
504 |a Rodriguez, J.B., (2001) Curr. Pharm. Des., 7, p. 1105 
504 |a Augustyns, K., Amssoms, K., Yamani, A., Rajan, P.K., Haemers, A., (2001) Curr. Pharm. Des., 7, p. 1117 
504 |a Cazzulo, J.J., Stoka, V., Turk, V., (2001) Curr. Pharm. Des., 7, p. 1143 
504 |a Docampo, R., (2001) Curr. Pharm. Des, 7, p. 1157 
504 |a Docampo, R., Moreno, S.N.J., (2001) Curr. Drug Targets Infect. Dis., 1, p. 51 
504 |a De Lederkremer, R.M., Bertello, L.E., (2001) Curr. Pharm. Des., 7, p. 1165 
504 |a Rodan, G.A., (1998) Annu. Rev. Pharmacol. Toxicol., 38, p. 375 
504 |a Rodan, G.A., Martin, T.J., (2000) Science, 289, p. 1508 
504 |a Reszka, A.A., Rodan, G.A., (2003) Curr. Rheumatol. Rep., 5, p. 65 
504 |a Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J., Frith, J.C., (2000) Cancer (Suppl.), 88, p. 2961 
504 |a Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D., Ebetino, F.H., Rogers, M.J., (2001) J. Pharmacol. Exp. Ther., 296, p. 235 
504 |a Yokoyama, K., Trobridge, P., Buckner, F.S., Scholten, J., Stuart, K.D., Van Voorhis, W.C., Gelb, M.H., (1998) Mol. Biochem. Parasitol., 94, p. 87 
504 |a Glomset, J.A., Farnswort, C.C., (1994) Annu. Rev. Cell. Biol., 10, p. 181 
504 |a Casey, P.J., Seabra, M., (1996) J. Biol. Chem., 271, p. 5289 
504 |a Leonard, D.M., (1997) J. Med. Chem., 40, p. 2971 
504 |a Van Beek, E., Pieterman, E., Cohen, L., Lowik, C., Papapoulos, S., (1999) Biochem Biophys. Res. Commun., 264, p. 108 
504 |a Keller, R.K., Fliesler, S.J., (1999) Biochem. Biophys. Res. Commun., 266, p. 560 
504 |a Bergstrom, J.D., Bostedor, R.G., Masarachia, P.J., Reszka, A.A., Rodan, G., (2000) Arch. Biochem. Biophys., 373, p. 231 
504 |a Cromartie, T.H., Fisher, K.J., Grossman, J.N., (1999) Pest Biochem. Physiol., 63, p. 114 
504 |a Grove, J.E., Brown, R.J., Watts, D.J., (2000) J. Bone Miner. Res., 15, p. 971 
504 |a Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hughes, D.E., Masarachia, P.J., Wesolowski, G., Reszka, A.A., (1999) Proc. Natl. Acad. Sci. U.S.A., 96, p. 133 
504 |a Martin, M.B., Arnold, W., Heath H.T. III, Urbina, J.A., Oldfield, E., (1999) Biochem. Biophys. Res. Commun., 263, p. 754 
504 |a Montalvetti, A., Bailey, B.N., Martin, M.B., Severin, G.W., Oldfield, E., Docampo, R., (2001) J. Biol. Chem., 276, p. 33930 
504 |a Urbina, J.A., Moreno, B., Vierkotter, S., Oldfield, E., Payares, G., Sanoja, C., Bailey, B.N., Docampo, R., (1999) J. Biol. Chem., 274, p. 33609 
504 |a Martin, M.B., Sanders, J.M., Kendrick, H., De Luca-Fradley, K., Lewis, J.C., Grimley, J.S., Van Bussel, E.M., Oldfield, E., (2002) J. Med. Chem., 45, p. 2904 
504 |a Martin, M.B., Grimley, J.S., Lewis, J.C., Heath H.T. III, Bailey, B.N., Kendrick, H., Yardley, V., Oldfield, E., (2001) J. Med. Chem., 44, p. 909 
504 |a Szajnman, S.H., Bailey, B.N., Docampo, R., Rodriguez, J.B., (2001) Bioorg. Med. Chem. Lett., 11, p. 789 
504 |a Lolli, M.L., Lazzarato, L., Di Stilo, A., Fruttero, R., Gasco, A., (2002) J. Organomet. Chem., 650, p. 77 
504 |a Sturtz, G., Guervenou, J., (1991) Synthesis, p. 661 
504 |a Degenhardt, C.R., Burdsall, D.C., (1986) J. Org. Chem., 51, p. 3488 
504 |a Bulman Page, P.C., Moore, J.P.G., Mansfield, I., McKenzie, M.J., Bowler, W.B., Gallagher, J.A., (2001) Tetrahedron, 57, p. 1837 
504 |a Wasielewski, C., Antczak, K., (1981) Synthesis, p. 540 
504 |a Gull, K., (2002) Curr. Pharm. Des., 8, p. 241 
504 |a Montalvetti, A., Fernandez, A., Sanders, J.M., Ghosh, S., Van Brussel, E., Oldfield, E., Docampo, R., (2003) J. Biol. Chem., 278, p. 17075 
504 |a Ogura, K., Nishino, T., Shinka, T., Seto, S., (1985) Methods Enzymol., 110, p. 167 
504 |a Tarshis, L.C., Proteau, P.J., Kellogg, B.A., Sacchettini, J.C., Poulter, C.D., (1996) Proc. Natl. Acad. Sci. U.S.A., 26, p. 15018 
520 3 |a Studies on the mode of action of a series of bisphosphonates derived from fatty acids, which had previously proved to be potent inhibitors against Trypanosoma cruzi proliferation in in vitro assays, have been performed. Some of these drugs proved to be potent inhibitors against the intracellular form of the parasite, exhibiting IC50 values at the low micromolar level. As bisphosphonates are FDA clinically approved for treatment of bone resorption disorders, their potential innocuousness makes them good candidates to control tropical diseases. © 2003 Elsevier Ltd. All rights reserved.  |l eng 
536 |a Detalles de la financiación: Fundación Antorchas 
536 |a Detalles de la financiación: National Council for Scientific Research, PIP 635/98 
536 |a Detalles de la financiación: Universidad de Buenos Aires, X-080 
536 |a Detalles de la financiación: This work was supported by grants from Fundación Antorchas, the National Research Council of Argentina (PIP 635/98), and the Universidad de Buenos Aires (X-080) to J.B.R., and the Illinois Governor's Venture Technology Program to R.D. 
593 |a Depto. de Quím. Orgán., Fac. de Ciencias Exactas y Naturales, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina 
593 |a Department of Pathobiology, Center for Zoonoses Research, Univ. of IL at Urbana-Champaign, 2001 South Lincoln Avenue, Urbana, IL 61802, United States 
690 1 0 |a FATTY ACID DERIVATIVE 
690 1 0 |a GERANYLTRANSFERASE 
690 1 0 |a PHOSPHONIC ACID DERIVATIVE 
690 1 0 |a ANOREXIA 
690 1 0 |a ARTICLE 
690 1 0 |a CELL PROLIFERATION 
690 1 0 |a DRUG APPROVAL 
690 1 0 |a DRUG POTENCY 
690 1 0 |a FOOD AND DRUG ADMINISTRATION 
690 1 0 |a IC 50 
690 1 0 |a IN VITRO STUDY 
690 1 0 |a INHIBITION KINETICS 
690 1 0 |a NONHUMAN 
690 1 0 |a OSTEOLYSIS 
690 1 0 |a PARASITE 
690 1 0 |a PERIPHERAL NEUROPATHY 
690 1 0 |a SKIN ALLERGY 
690 1 0 |a TROPICAL DISEASE 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a VOMITING 
690 1 0 |a TRYPANOSOMA 
690 1 0 |a TRYPANOSOMA CRUZI 
700 1 |a Montalvetti, A. 
700 1 |a Wang, Y. 
700 1 |a Docampo, R. 
700 1 |a Rodriguez, J.B. 
773 0 |d Elsevier Ltd, 2003  |g v. 13  |h pp. 3231-3235  |k n. 19  |p Bioorg. Med. Chem. Lett.  |x 0960894X  |w (AR-BaUEN)CENRE-3990  |t Bioorganic and Medicinal Chemistry Letters 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0041330424&doi=10.1016%2fS0960-894X%2803%2900663-2&partnerID=40&md5=015fea27cd03f3571cfa5903999e7c96  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1016/S0960-894X(03)00663-2  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_0960894X_v13_n19_p3231_Szajnman  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0960894X_v13_n19_p3231_Szajnman  |y Registro en la Biblioteca Digital 
961 |a paper_0960894X_v13_n19_p3231_Szajnman  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 65768